<DOC>
	<DOCNO>NCT02600325</DOCNO>
	<brief_summary>New recently EMA/FDA approve direct act antiviral ( DAA ) combination therapy cure 95 % patient chronically infect HCV genotype 1 4 . Grazoprevir ( MK-5172 ) elbasvir ( MK-8742 ) combination therapy , albeit yet EMA/FDA approve combination DAA therapy . It likely synergistic effect host 's immune response antiviral therapy give first 6 month HCV infection make antiviral therapy acute HCV infection effective . In study investigator would like document treatment acute HCV grazoprevir ( MK-5172 ) , elbasvir ( MK-8742 ) effective ben shorten 12 8 week HCV genotype 1 4 infection without substantial loss efficacy . Study design intervention : Prospective open label interventional clinical trial 80 acute HCV genotype 1 4 patient co-infected HIV receive 8 week grazoprevir elbasvir ( once-daily combination tablet ) . Study population : 80 Adult HIV positive patient acute HCV genotype 1 4 infection 10 HIV treatment center Netherlands Belgium include . Primary endpoint : Sustained viral response ( SVR ) 12 week end therapy ITT study population ( =genotype 1 4 ) .</brief_summary>
	<brief_title>Dutch Acute HCV HIV Study ( DAHHS-2 ) : Grazoprevir/Elbasvir Acute HCV</brief_title>
	<detailed_description>Rationale : Over last 2 year , treatment chronic HCV underwent enormous change positive way . New recently EMA approve direct act antiviral ( DAA ) combination therapy cure 95 % patient chronically infect HCV genotype 1 4 . Grazoprevir ( MK-5172 ) elbasvir ( MK-8742 ) combination therapy combination DAA therapy . Two recent phase II 1 phase III clinical trial show chronic HCV genotype 1 cure 12 week combination therapy grazoprevir elabsvir 97 % cure HIV-HCV co-infected patient phase III C-Edge co-infection study . However , none new HCV therapy well study treatment acute HCV therefore register indication . The treatment approve acute HCV interferon . Interferon base therapy treatment HCV show much effective give acute phase HCV infection time infection become chronic . A likely explanation difference success acute versus chronic HCV therapy substantial immune response present acute phase HCV infection , becomes exhaust chronic infection . This potent immune response broadly target various HCV epitopes eradicate approximately 20 % HCV infection within first 12 18 month infection . However , spontaneous cure HCV become rare first 12 18 month infection due immune exhaustion . It likely synergistic effect host 's immune response antiviral therapy give first 6 month HCV infection make direct act antiviral therapy acute HCV infection effective . Objectives : To document treatment acute HCV grazoprevir ( MK-5172 ) , elbasvir ( MK-8742 ) effective . To show , due host 's immune response time acute HCV infection , duration therapy grazoprevir ( MK-5172 ) elbasvir ( MK-8742 ) acute HCV genotype 1 4 infection shorten 12 8 week without substantial loss efficacy .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>1 . HIV positive 2 . Acute HCV genotype 1 4 infection ( ≤26 week old baseline visit ) 1 . Not cART CD4 &lt; 500 time screen 2 . Patients cART &gt; 6 month HIV viral load &gt; 400 copy 3 . Disallowed comedication stop replace 4 . History liver cirrhosis etiology . Inclusion patient chronic wellcontrolled HBV ( HBVDNA &lt; limit detection ) allow fibroscan excludes &gt; F1 fibrosis 5 . Protease inhibitor base NNRTI base cART regimens allow . Therefore , inability switch HAART regimen consist 2 nucleoside/tide reverse transcriptase inhibitor allow third agent raltegravir ( Isentress® ) 400mg BID , dolutegravir ( Tivicay ) 50mg QD rilpivirine 25mg QD .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Acute Hepatitis C</keyword>
	<keyword>Human Immunodeficiency virus</keyword>
	<keyword>Grazoprevir</keyword>
	<keyword>Elbasvir</keyword>
</DOC>